A formal memorandum of understanding between the Oslo Cancer Cluster in Oslo, Norway, and the US-based Hamner Institute for Life Science has been set up in a bid to strengthen research and drug development ties across the Atlantic.
The main goal of the collaboration is to strengthen the Hamner’s Global BioScience Gateway for Translational Research and Business Development through its partnership with the Oslo Cancer Cluster.
The partnership will create an infrastructure in North Carolina and Oslo to boost drug discovery, oncology clinical trials and provide access to drug safety and regulatory experts that can address the FDA, EMEA and eventually the Chinese SFDA.
Oslo Cancer Cluster CEO Bjarte Reve said that the company had already seen concrete results, such as a Phase I network and joint EU-IMI submissions.
“This partnership with the Hamner is a logical next step to forge stronger links with the US and also to complement our existing initiatives in China,” Reve said.
Specific initiatives of the Hamner-Oslo collaboration will focus on translational research, business development, and training and education.
The Hamner will provide access to its wide network of research collaborators, including three comprehensive cancer centres located in North Carolina, the Shanghai Center for Disease Control, and the Tianjin Institute for Hematology.
Training and education will include post-doctoral training in innovative drug safety technologies, business training for entering the US market, and regulatory training for compliance with FDA standards.
Oslo will provide research and Phase I resources, and potential future access to its own growing European network of collaborators, which includes Heidelberg, Lund, Toulouse, Barcelona and Madrid.